Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Kunxian Capsule in Treatment Patients With Early Ankylosing Spondylitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 16 to 65 years old, having signed the informed consent;~* fulfill the ESSG criteria for diagnosis of SpA; not fulfill the 1984 modified NewYork criteria for AS;~* BASDAI score more than 4;~* stop taking DMARDs for at least 4 weeks;~* NSAIDs dosage has been stable for at least 4 weeks;~Exclusion Criteria:~* Intra-articular injection of cortisone within 3 months.~* History of heart failure, multiple sclerosis, COPD, lymphoma or other tumors;~* Accompanied by fibromyalgia or other rheumatic diseases;~* Female of pregnancy or breast feeding;~* History of mental disease and poor compliance.~* History of drug abuse or alcoholism.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Sulfasalazine (Type: ACTIVE_COMPARATOR): Sulfasalazine is a drug in treatment RA, AS and ulcerative colonitis. In this study, Sulfasalazine is used to act as an active comparator to access the efficacy of kunxian capsule.
- placebo (Type: PLACEBO_COMPARATOR): The placebo capsule was used to be a comparator of kunxian capsule

Based on this trial design, predict the completion outcome and termination type (if applicable).